Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.

PPMI Enrollment Status

Prodromal Participants
Enrollment Goal: 100

Genetic Cohort Participants
Enrollmen Goal: 600

Genetic Registry Participants
Enrollment Goal: ~600

De Novo PD Participants
Enrollment Goal: 400

Control Participants
Enrollment Goal: 200

Subjects with SWEDD
Enrollment: 64

Last Update: November 24, 2014


More about study cohorts >


Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.

PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.

PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.

Learn more about Who We Are.


Video: Thank you from Michael J. Fox

Michael J. Fox has created an exclusive video thanking the PPMI volunteers and researchers for their exceptional contributions to Parkinson’s research.

Over 22,000 Samples Currently Available

PPMI has been actively collecting a wealth of biospecimens from the study participants, a group that has now grown to over 800 enrolled individuals. The samples are standardized, longitudinal, and available to qualified researchers conducting biomarker verification studies.

PPMI Presentation at the Parkinson’s Disease Therapeutics Conference 10/29

PPMI’s principal investigator, Dr. Ken Marek, will present on the initial findings of PPMI at the 8th Annual Parkinson’s Disease Therapeutics Conference on October 29 in New York City.

Participant Study Update Call on PPMI Imaging

The audio from the latest PPMI Participant Study Update Call has just been posted. On the call, the principal investigator of the PPMI Imaging Core, John Seibyl, MD of Molecular Neuroimaging, LLC, discusses the role of imaging in PPMI. Listen to this call and find an archive of the past calls here.

New Publication on SPECT Imaging and Executive Function

A new study using PPMI data was published in the journal Movement Disorders exploring the relationship between cognitive impairment and dopaminergic deficits in unmedicated Parkinson’s patients.

Learn More